Doorbreek Dwang Digitaal

Gepubliceerd: 24-12-2019 Laatst bijgewerkt: 15-05-2024

We expect to find a difference in treatment effect with a small to medium effect size in favour of the experimental condition

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON22344

Bron Nationaal Trial Register

Verkorte titel Het 3D - Onderzoek

Aandoening

Obsessive-compulsive disorder

Ondersteuning

Primaire sponsor: none Overige ondersteuning: none

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

difference in treatment outcome as measured with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

Toelichting onderzoek

Achtergrond van het onderzoek

Rationale: This study aims to compare personalized exposure and ESM feedback sessions with exposure as usual in patients with obsessive-compulsive disorder. Personalized exposure will be provided according to individual needs face-to-face as well as screen-to-screen in ecological valid situation by means of the app NiceDay. This app will also be used as a data collection tool during therapy. By means of experience sampling methodology (ESM) objective and subjective data in realtime and real-place will be systematically collected. Personalized feedback based on ESM data will be used to identify triggers and protective factors for symptom severity and to optimize the effect of ERP. Objective: The primary goal of the project is to investigate the effectiveness of providing personalized mental health care to patients with OCD, compared to exposure and response prevention (ERP) in the traditional context of a therapist's room. Evidence based treatment (ERP) will be personalized by using a smartphone app (NiceDay) as a tool to increase ecological validity of exercises, by conducting them into patients 'real time and world'. A second goal is to assess if there is a difference in relapse rates and patterns between patients receiving personalized ERP compared to ERP as usual. A third goal of this study is to identify different subgroups of patients on a network level in order to create more insight in the heterogenic group of OCD patients. With these networks we aim to determine predictors for treatment success and relapse. A fourth goal is to explore if our treatment approach increases patients' self-efficacy and active participation in the therapeutic process and to investigate whether this influences treatment effect. Finally, we are interested in how feasible the use of a smartphone app, network models and personalized feedback is in perception of both patients and therapists.

Study design: The design of the study will be a 20 sessions (on a weekly basis) 2 group (ERP as

usual versus personalized ERP) randomized controlled clinical trial with repeated

2 - Doorbreek Dwang Digitaal 20-05-2025

measurements at baseline (T0), 5 weeks of treatment (T1), 10 weeks of treatment (T2), 15 weeks of treatment (T3), posttest at 20 weeks (T4), 6 weeks follow-up (T5), 3 months follow-up (T6), 6 months followup (T7) and a year follow-up (T8).

Study population: The study will be conducted in 160 patients with an OCD diagnosed according to DSM 5 criteria.

Intervention (if applicable): One group will receive exposure with response prevention as usual, the other group will receive personalized exposure with response prevention with smartphone application NiceDay and personalized feedback sessions based on experience sampling data.

Main study parameters/endpoints: The main study parameter is a difference in treatment outcome as measured with the Y-BOCS.

Doel van het onderzoek

We expect to find a difference in treatment effect with a small to medium effect size in favour of the experimental condition

Onderzoeksopzet

9

Onderzoeksproduct en/of interventie

Exposure as usual Personalized Exposure

Contactpersonen

Publiek

PsyQ Elena Hoogerwerf

088-3572759

Wetenschappelijk

PsyQ Elena Hoogerwerf

088-3572759

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

An OCD diagnosis according to DSM 5 criteria. Furthermore, they should not have received any

treatment for OCD in the past 3 months, medication has to be stable for at least three months and patients

have to be willing to refrain from following other treatment for OCD and keep possible medication

stabile during the experimental part of the study. When entering the naturalistic follow-up phase

the restrictions will be released.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Since the focus of the research project is related to personalized care, taking into account the heterogeneity of OCD symptoms and individual, social and contextual differences between patients,

we will be economical with exclusion criteria. Therefore, our exclusion criteria will only relate to our obligation

to offer appropriate care and to guarantee patient safety. So, only patients who suffer from severe

comorbidity in the psychiatric field (psychosis, addiction/intoxication) will be excluded from participation

in this study. Furthermore, since the treatment and questionnaires will be in Dutch insufficient

fluency in the Dutch language is also a criterion for exclusion.

Onderzoeksopzet

Opzet

Туре:	Interventie onderzoek
Onderzoeksmodel:	Anders
Toewijzing:	Gerandomiseerd
Blindering:	Enkelblind
Controle:	Geneesmiddel

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	24-12-2019
Aantal proefpersonen:	160
Туре:	Verwachte startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nog niet bepaald

Ethische beoordeling

Positief advies	
Datum:	24-12-2019
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 55600 Bron: ToetsingOnline Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL8254
ССМО	NL68816.058.19
OMON	NL-OMON55600

Resultaten